Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer

Inclusion Criteria:

A patient will be considered for enrollment in this study if all the following criteria are met:

1. Female patients ≥18 years of age.
2. Have TNBC defined as invasive ductal cancer: ER- tumors with \<10% of tumor nuclei immunoreactive; PR- tumors with \<10% of tumor nuclei immunoreactive; HER2-negative defined as follows:

   1. FISH-negative (FISH ratio \<2.0), or
   2. IHC 0-1+, or
   3. IHC 2+ AND FISH-negative (FISH ratio\<2.0)
3. Adequate hematologic function, defined by:

   1. Absolute neutrophil count (ANC) \>1000/mm3
   2. Platelet count ≥100,000/mm3
   3. Hemoglobin \>9 g/dL (in the absence of red blood cell transfusion)
4. Adequate liver function, defined by:

   1. AST and ALT ≤ 5 x the upper limit of normal (ULN)
   2. Total bilirubin ≤1.5 x ULN
5. Adequate renal function, defined by:

   a. Serum creatinine ≤ 2 x ULN or calculated creatinine clearance of ≥60 ml/min
6. Have blood glucose \<250 mg/dL
7. Willing to undergo 1 mandatory core biopsy (6 passes) for research purposes.
8. All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry.

Exclusion Criteria:

A patient will be ineligible for inclusion in this study any of the following criteria are met:

1. Patients receiving any anti-cancer therapy (chemotherapy, immunotherapy, and/or biologic therapy).
2. Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study.
3. Has a history of insulin-dependent diabetes.
4. Concomitant active malignancy
5. Is pregnant or breastfeeding.